Marie‐paule Kieny

Marie‐paule Kieny's AcademicInfluence.com Rankings

Marie‐paule Kieny

Biology

#11924

World Rank

#15359

Historical Rank

Virology

#286

World Rank

#293

Historical Rank

Immunology

#786

World Rank

#809

Historical Rank

biology Degrees

Download Badge

Biology

Marie‐paule Kieny's Degrees

PhD Immunology University of Strasbourg

Why Is Marie‐paule Kieny Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Marie‐paule Kieny's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results (2020) (2026)
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) (2017) (716)
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial (2015) (685)
Cost–effectiveness thresholds: pros and cons (2016) (467)
The 2009 A (H1N1) influenza virus pandemic: A review. (2010) (454)
Expression of rabies virus glycoprotein from a recombinant vaccinia virus (1984) (426)
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. (2016) (389)
Monitoring Progress towards Universal Health Coverage at Country and Global Levels (2014) (375)
SARS-CoV-2 variants and ending the COVID-19 pandemic (2021) (374)
Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. (1991) (350)
Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. (1984) (349)
Delivering Quality Health Services: A Global Imperative for Universal Health Coverage (2018) (306)
Medication Without Harm: WHO's Third Global Patient Safety Challenge (2017) (289)
Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine (1991) (276)
Oral vaccination of the fox against rabies using a live recombinant vaccinia virus (1986) (247)
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. (2015) (246)
Mucosal immunity and tolerance: relevance to vaccine development (1999) (241)
The international Ebola emergency. (2014) (229)
New versatile cloning and sequencing vectors based on bacteriophage M13. (1983) (228)
A review of vaccine research and development: human enteric infections. (2006) (219)
Membrane expression of HIV envelope glycoproteins triggers apoptosis in CD4 cells. (1993) (217)
Cyp7b, a novel brain cytochrome P450, catalyzes the synthesis of neurosteroids 7α-hydroxy dehydroepiandrosterone and 7α-hydroxy pregnenolone (1997) (204)
A review of vaccine research and development: meningococcal disease. (2006) (202)
Protein-Protein Interactions between Hepatitis C Virus Nonstructural Proteins (2003) (201)
First generation leishmaniasis vaccines: a review of field efficacy trials. (2008) (192)
Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial (2016) (190)
Universal health coverage. (2013) (187)
A review of vaccine research and development: Human acute respiratory infections (2005) (186)
Health-system resilience: reflections on the Ebola crisis in western Africa (2014) (176)
Strengthening health systems for universal health coverage and sustainable development (2017) (175)
A review of vaccine research and development: the human immunodeficiency virus (HIV). (2006) (172)
Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. (1991) (168)
Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. (1992) (160)
A review of human vaccine research and development: malaria. (2007) (157)
Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of the HIV-1 NEF protein. (1991) (144)
Developing Global Norms for Sharing Data and Results during Public Health Emergencies (2016) (144)
Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins (1989) (140)
A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. (1995) (140)
Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the central African Republic. (1993) (139)
Linker tailing: unphosphorylated linker oligonucleotides for joining DNA termini. (1984) (135)
Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. (2008) (134)
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. (2016) (133)
Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. (2011) (132)
Ebola vaccine--an urgent international priority. (2014) (120)
Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. (2012) (113)
Rationale for WHO's New Position Calling for Prompt Reporting and Public Disclosure of Interventional Clinical Trial Results (2015) (111)
Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. (1990) (109)
Mutational analysis of the HIV nef protein. (1990) (108)
Priority-setting for achieving universal health coverage (2016) (105)
Development of a Mouse Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis in Humans (2009) (102)
Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. (2006) (101)
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1 (1995) (99)
Tumour prevention and rejection with recombinant vaccinia (1987) (98)
Beyond Ebola: a new agenda for resilient health systems (2015) (98)
Carboxyl-terminal and central regions of human immunodeficiency virus-1 NEF recognized by cytotoxic T lymphocytes from lymphoid organs. An in vitro limiting dilution analysis. (1992) (98)
Advancing the Right to Health-The Vital Role of Law. (2017) (96)
MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines (2000) (95)
Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV (2017) (95)
Improved antigenicity of the HIV env protein by cleavage site removal. (1988) (94)
Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein. (1991) (94)
AIDS virus env Protein Expressed from a Recombinant Vaccinia Virus (1986) (92)
Safety of the Recombinant Cholera Toxin B Subunit, Killed Whole-Cell (rBS-WC) Oral Cholera Vaccine in Pregnancy (2012) (88)
A global pandemic influenza vaccine action plan. (2006) (88)
Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets. (2010) (88)
WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. (2011) (87)
Cytotoxic T lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques. (1992) (80)
Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen. (1993) (80)
USE OF RECOMBINANT VACCINIA-RABIES GLYCOPROTEIN VIRUS FOR ORAL VACCINATION OF WILDLIFE AGAINST RABIES: INNOCUITY TO SEVERAL NON-TARGET BAIT CONSUMING SPECIES (1989) (79)
Isotypic restriction of the antibody response to human immunodeficiency virus. (1988) (79)
Safety and Immunogenicity of a Malaria Vaccine, Plasmodium falciparum AMA-1/MSP-1 Chimeric Protein Formulated in Montanide ISA 720 in Healthy Adults (2008) (79)
The alpha-glucosidase inhibitor 1-deoxynojirimycin blocks human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step. (2002) (77)
A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein (1991) (76)
Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa (1996) (74)
HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques (1995) (74)
Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. (2005) (73)
Qualitative and quantitative analysis of human cytotoxic T‐lymphocyte responses to HIV‐1 proteins (1992) (73)
Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report (2017) (73)
The Zika Challenge. (2016) (71)
Cytotoxic T cells in HIV2 seropositive Gambians. Identification of a virus-specific MHC-restricted peptide epitope. (1993) (70)
Research agenda for mass gatherings: a call to action (2012) (69)
Global production capacity of seasonal influenza vaccine in 2011. (2013) (69)
Loss of CD4 membrane expression and CD4 mRNA during acute human immunodeficiency virus replication (1988) (67)
Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization☆ (2017) (63)
4th meeting on Novel Adjuvants Currently in/close to Human Clinical Testing World Health Organization -- organisation Mondiale de la Santé Fondation Mérieux, Annecy, France, 23-25, June 2003. (2004) (63)
Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160. (1996) (63)
The third global patient safety challenge: tackling medication-related harm. (2017) (62)
Data sharing in public health emergencies: a call to researchers (2016) (62)
Molecular cloning and tissue distribution of a 26-kilodalton Schistosoma mansoni glutathione S-transferase. (1990) (58)
Primary multiplication site of the vaccinia-rabies glycoprotein recombinant virus administered to foxes by the oral route. (1990) (55)
Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients. (1994) (54)
Use of recombinant vaccinia-rabies virus for oral vaccination of fox cubs (Vulpes vulpes, L) against rabies. (1988) (53)
Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial (2017) (51)
A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation (2016) (51)
Secondary Structure of the 3′ Terminus of Hepatitis C Virus Minus-Strand RNA (2002) (51)
Production of cholera toxin B subunit in Lactobacillus. (1998) (50)
Comparative Vaccine Studies in HLA-A2.1-Transgenic Mice Reveal a Clustered Organization of Epitopes Presented in Hepatitis C Virus Natural Infection (2002) (48)
Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009. (2009) (47)
Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV‐1 by deletion of the env amino‐terminal signal sequence (1990) (47)
Complex systems analysis: towards holistic approaches to health systems planning and policy. (2011) (45)
On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014-2016 Ebola epidemic in West Africa. (2016) (44)
A review of vaccine research and development: tuberculosis. (2005) (44)
Assembling a global vaccine development pipeline for infectious diseases in the developing world. (2006) (43)
Development of a Vaccinia-Rabies Glycoprotein Recombinant Virus Vaccine (1988) (42)
Multiple subsets of HIV‐specific cytotoxic T lymphocytes in humans and in mice (1989) (41)
Cholera in disasters: do vaccines prompt new hopes? (2008) (41)
Identification of a neutralizing domain in the external envelope glycoprotein of simian immunodeficiency virus. (1992) (41)
World Health Organization Methodology to Prioritize Emerging Infectious Diseases in Need of Research and Development (2018) (40)
Malaria vaccine development: progress and challenges. (2006) (40)
An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope. (1990) (40)
Development of vaccines against influenza H5. (2006) (40)
Towards a global definition of responsible antibiotic use: results of an international multidisciplinary consensus procedure (2018) (39)
Development and evaluation of influenza pandemic vaccines (2006) (38)
Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain (1993) (37)
The impact of globalization on vaccine development and availability. (2006) (36)
High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env, rev, tat, and vpu genes from HIV-1 Lai. (1996) (35)
The Evolution of the Meningitis Vaccine Project (2015) (35)
Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1. (1997) (35)
H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial. (2016) (34)
Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline. (2019) (34)
Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010. (2010) (34)
HCV core, NS3, NS5A and NS5B proteins modulate cell proliferation independently from p53 expression in hepatocarcinoma cell lines (2004) (34)
Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. (2004) (33)
Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits. (2009) (32)
Hepatitis C virus IRES efficiency is unaffected by the genomic RNA 3'NTR even in the presence of viral structural or non-structural proteins. (2003) (31)
Production of a non-functional nef protein in human immunodeficiency virus type 1-infected CEM cells. (1990) (30)
Human vaccine research and development: an overview. (2005) (30)
Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses. (1989) (30)
Use of vaccinia rabies recombinant for oral vaccination of wildlife. (1990) (30)
Ethical considerations related to the provision of care and treatment in vaccine trials. (2007) (30)
Research and development of new vaccines against infectious diseases. (2004) (29)
Persistence of Pathogenic Challenge Virus in Macaques Protected by Simian Immunodeficiency Virus SIVmacΔnef (2001) (28)
Human resources for universal health coverage: from evidence to policy and action. (2013) (26)
Recombinant cholera toxin B subunit in Escherichia coli: high-level secretion, purification, and characterization. (1994) (26)
HIV-1 core proteins expressed from recombinant vaccinia viruses. (1989) (26)
Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins. (1991) (25)
2009 Pandemic influenza A virus subtype H1N1 vaccination in Africa--successes and challenges. (2012) (25)
Immunization safety priority project at the World Health Organization. (2003) (25)
Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. (1995) (25)
WHO R&D Blueprint: a global coordination mechanism for R&D preparedness (2017) (25)
Vaccinia recombinants expressing early bovine papilloma virus (BPV1) proteins: retardation of BPV1 tumour development. (1990) (24)
Detectable Vesicular Stomatitis Virus (VSV)–Specific Humoral and Cellular Immune Responses Following VSV–Ebola Virus Vaccination in Humans (2018) (24)
The need for global R&D coordination for infectious diseases with epidemic potential (2016) (23)
Targeted macrophage cytotoxicity using a nonreplicative live vector expressing a tumor-specific single-chain variable region fragment. (2000) (23)
Third meeting on Novel Adjuvants Currently in or Close to Clinical Testing World Health Organization--Organisation Mondiale de la Santé, Fondation Mérieux, Annecy, France, 7-9 January 2002. (2003) (23)
Interaction between rabies infection and oral administration of vaccinia-rabies recombinant virus to foxes (Vulpes vulpes). (1989) (23)
Tough decisions on essential medicines in 2015 (2015) (22)
Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial (2017) (22)
M13 bacteriophage vectors for the expression of foreign proteins in Escherichia coli: the rabies glycoprotein. (1984) (22)
Patent pooling to increase access to essential medicines (2019) (22)
Trypsin-resistant gp120 receptors are upregulated on short-term cultured human epidermal Langerhans cells. (1991) (22)
HIV‐specific T lymphocyte immunity in mice immunized with a recombinant vaccinia virus (1988) (22)
Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009. (2010) (22)
Vaccinia recombinants expressing secreted and transmembrane forms of breast cancer-associated epithelial tumour antigen (ETA). (1991) (21)
DNA binding factors that bind to the negative regulatory element of the human immunodeficiency virus-1: regulation by nef. (1990) (21)
Tumor gene therapy by MVA-mediated expression of T-cell–stimulating antibodies (2002) (21)
Effi cacy and eff ectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein : interim results from the Guinea ring vaccination cluster-randomised trial (2015) (20)
The 2014 Ebola outbreak: ethical use of unregistered interventions (2014) (20)
Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein. (1990) (19)
Seasonal vaccines – Critical path to pandemic influenza response (2017) (19)
Interaction of Human Epidermal Langerhans Cells with HIV‐1 Viral Envelope Proteins (gp 120 and gp 160s) Involves a Receptor‐mediated Endocytosis Independent of the CD4 T4A Epitope (1991) (19)
Reducing empiricism in malaria vaccine design. (2010) (18)
Report of the third meeting on "influenza vaccines that induce broad spectrum and long-lasting immune responses", World Health Organization, Geneva, Switzerland, 3-4 December 2007. (2008) (18)
Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model (2018) (18)
Lack of evidence for an immunosuppressive role for MUC1 (1999) (18)
Technology transfer hub for pandemic influenza vaccine. (2009) (17)
Lessons learned from Ebola Vaccine R&D during a public health emergency (2018) (16)
Directed cytokine expression in tumour cells in vivo using recombinant vaccinia virus. (1994) (16)
Influenza pandemic vaccines: how to ensure a low-cost, low-dose option (2006) (15)
Gender, age, and ethnicity in HIV vaccine-related research and clinical trials: Report from a WHO–UNAIDS consultation, 26–28 August 2004. Lausanne, Switzerland (2005) (15)
Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability. (2018) (14)
The pandemic influenza vaccine challenge. (2008) (14)
Correction: Development of a Mouse Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis in Humans (2009) (14)
Cloned antigens and antiidiotypes. (1995) (12)
In vitro binding and internalization of HIV envelope glycoproteins by human epidermal Langerhans cells does not require the CD4-gp120-binding site. (1990) (12)
Report of the second meeting on the development of influenza vaccines that induce broad-spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 6-7 December 2005. (2006) (12)
Development of animal recombinant DNA vaccine and its efficacy in foxes. (1988) (12)
The WHO we want (2020) (12)
A novel transgenic mouse model for the in vivo evaluation of anti-human immunodeficiency virus type 1 drugs. (1992) (12)
Different approaches to influenza vaccination. (2006) (12)
Informing the establishment of the WHO Global Observatory on Health Research and Development: a call for papers (2015) (12)
Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report (2019) (12)
Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody (2000) (12)
Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization (1994) (11)
A roadmap for sustainably governing the global antimicrobial commons (2019) (11)
Structure and regulation of the human AIDS virus. (1990) (11)
Best practices for sharing information through data platforms: establishing the principles (2016) (11)
Feasibility of developing live attenuated HIV vaccines: conclusions and recommendations. World Health Organization Working Group. (1994) (11)
[Safety and efficacy of an antirabies vaccine consisting of recombinant vaccinia-rabies virus administered orally to the fox, dog and cat]. (1989) (11)
Heterologous HIV-2 challenge of rhesus monkeys immunized with recombinant vaccinia viruses and purified recombinant HIV-2 proteins. (1995) (11)
An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step. (2000) (10)
Analysis of the subcellular localization of hepatitis C virus E2 glycoprotein in live cells using EGFP fusion proteins. (2003) (10)
Honouring the value of people in public health: a different kind of p-value (2015) (10)
HIV-1 env, nef, and gag-specific T-cell immunity in mice: conserved epitopes in nef p27 and gag p25 proteins. (1992) (10)
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013–2016 West Africa Ebola outbreak in Guinea (2020) (9)
The promise of conjugate vaccines for Africa. (2007) (9)
Multiple cytotoxic effector cells are induced by infection with the human immunodeficiency virus. (1989) (9)
Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines. (1997) (9)
Rabies vaccine: traditional and novel approaches. (1987) (8)
Strain specificity of cell-mediated cytotoxic responses specific for the human immunodeficiency virus type 1 (HIV-1) envelope protein in seropositive donors: HIV-1Lai is more commonly recognized than HIV-1MN. (1994) (8)
Guidelines for the evaluation of dengue vaccines in populations exposed to natural infection (2002) (8)
Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination (2020) (8)
Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth (2001) (8)
Reboot biomedical R&D in the global public interest (2022) (8)
Effi cacy and eff ectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease : fi nal results from the Guinea ring vaccination , open-label , cluster-randomised trial ( Ebola Ça Suffi t ! ) (2017) (7)
Report of the 4th meeting on the "Evaluation of pandemic influenza prototype vaccines in clinical trials." World Health Organization, Geneva, Switzerland, 14-15 February 2008. (2008) (7)
Developing a vaccine against Zika (2016) (7)
Characterization of polyoma virus early proteins expressed from vaccinia virus recombinants. (1988) (7)
Next Generation Inactivated Poliovirus Vaccine: The Future Has Arrived. (2017) (7)
Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination (2020) (7)
Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice. (1995) (7)
Global platform to inform investments for health R&D (2016) (7)
Preparedness for Infectious Threats (2007) (7)
Kex2p: a model for cellular endoprotease processing human immunodeficiency virus type 1 envelope glycoprotein precursor. (1994) (6)
WHO supports fair access to influenza A (H1N1) vaccine. (2009) (6)
What if communities held the solutions for universal health coverage? (2019) (6)
Questionable efficacy of the rVSV-ZEBOV Ebola vaccine – Authors' reply (2018) (6)
Regulatory policy for research and development of vaccines for public health emergencies (2016) (6)
Health policy and systems research: building momentum and community (2014) (6)
Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. 1984. (1992) (6)
Systems science for universal health coverage (2017) (6)
Changes in the primary outcome in Ebola vaccine trial – Authors' reply (2016) (5)
Building the Human Vaccines Project: strategic management recommendations and summary report of the 15–16 July 2014 business workshop (2015) (5)
Recombinant polyoma--vaccinia viruses: T antigen expression vectors and anti-tumor immunization agents. (1988) (5)
Recombinant CD63/ME491/Neuroglandular/NKI/C-3 Antigen Inhibits Growth of Established Tumors in Transgenic Mice 1 (2003) (5)
European Union conference on poverty-related diseases research. (2009) (5)
Putting health policy and systems research on the map. (2012) (5)
The E2 trans-activating protein of bovine papillomavirus type 1 (BPV1) is serine-phosphorylated in vivo. (1989) (5)
Self-association of truncated forms of HIV-1 gp120. (1997) (5)
Antiplatelet antibodies during the course of HIV-preventive vaccine trial. (1996) (4)
The HIV Nef protein: facts and hypotheses. (1992) (4)
[COVID-19 vaccination for cancer patients: Medical and ethical need]. (2021) (4)
Specific tumor cell targeting by a recombinant MVA expressing a functional single chain antibody on the surface of intracellular mature virus (IMV) particles. (2007) (4)
Preparedness for infectious threats: public-private partnership to develop an affordable vaccine for an emergent threat: the trivalent Neisseria meningitidis ACW135 polysaccharide vaccine. (2007) (4)
New influenza A(H1N1) vaccine: How ready are we for large-scale production? (2009) (4)
In vivo delivery of interleukin-6 using vaccinia virus: effects on T lymphocytes in nude mice. (1991) (4)
Isolation of recombinant partial gag gene product p18 (HIV-1Bru) from Escherichia coli. (1989) (4)
Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials. (2009) (4)
A vaccine against malaria: a substantial step forward (2009) (3)
Public health: Use open data to curb Zika virus (2016) (3)
Europe and the century of biomedical discovery and implementation. (2011) (3)
Health Systems Global, the new international society for health systems research. (2012) (3)
Towards access 2030 (2017) (3)
French research strategy to tackle antimicrobial resistance (2020) (3)
Research priorities to increase vaccination coverage in Europe (EU joint action on vaccination). (2021) (3)
Eﬃ cacy and eﬀ ectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: ﬁ nal results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suﬃ t!) (2017) (2)
Monitoring progress towards universal health coverage: recent developments. (2014) (2)
A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project (2022) (2)
[Experience with antirabies vaccination of foxes using the oral route coordinated among several European countries and perspectives on the use of recombinant vaccinia-rabies virus]. (1988) (1)
Systematic Analysis of Evidence and Sound Expert Assessment: Two Enablers of Evidence‐Based Decision‐Making in Health (2018) (1)
Adding to the mantra: vaccines prevent illness and death, and preserve existing antibiotics. (2022) (1)
AIDS Vaccine Development: Challenges and Opportunities (2007) (1)
Candidate vaccines for HIV (1989) (1)
[HIV envelope proteins are bound by human epidermal Langerhans cells by a binding site which differs from the site on the CD4 molecule, and are internalized by receptor endocytosis]. (1989) (1)
[Experimental vaccination against HIV-1 protects the chimpanzee against challenge with injections of infected lymphocytes]. (1992) (1)
One attack on a health worker is one too many (2017) (1)
Satellite Symposium on Challenges to Enteric Vaccines (2007) (1)
[Malaria vaccines: state of advancement]. (2003) (1)
Author Correction: Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination (2020) (1)
Vaccination against papovavirus-induced tumours using vaccinia recombinants expressing non-structural proteins (1989) (1)
viral vector and recombinant DNA coding for the F protein of the virus causative agent of AIDS, cell culture infected by this vector, method of preparing the protein, protein obtained, vaccine and antibody obtained (1986) (0)
Proteine antigenique de la rage glycosylee (1984) (0)
Antitumor compilation of immunogenic polypetiden with altered zellokalisierung (1998) (0)
Vectors for expressing a antigenic rabies protein in eucaryotic cells and their application in the preparation of a vaccine (1983) (0)
New expression vectors of the antigenic protein of rabies and their application in the preparation of vaccines (1982) (0)
Satellite Symposium on Challenges to Enteric Vaccines: Salvador de Bahia, Brazil, 12 June 2005 (2007) (0)
A pharmaceutical composition against tumors and infections caused by papilloma viruses (1997) (0)
Alteration ofV3LoopContext within theEnvelope ofHuman Immunodeficiency Virus Type1Enhances Neutralization (1994) (0)
Vaccinia/polyoma recombinant virus: A model for tumour immunity (1987) (0)
Pharmaceutical composition for the treatment or prevention of malignant tumors (1991) (0)
Eradication of Sylvatic Rabies Using a Live Recombinant Vaccinia-Rabies Vaccine (1993) (0)
Secondary Structure of the 3 (cid:2) Terminus of Hepatitis C Virus Minus-Strand RNA (2002) (0)
Protein, dna sequence, poxviruses, and cell culture process, as well as pharmaceutical compositions thereof, useful in the prevention of schistosomiasis (1986) (0)
Fifth International Conference on AIDS : the Scientific and Social Challenge; plenary session; synthesis (1989) (0)
viral vector and recombinant DNA coding for a glycoprotein of the virus causative agent of AIDS, cell culture infected by this vector, process for the preparation of the glycoprotein, glycoprotein obtained, vaccine and antibody obtained (1986) (0)
An antitumor composition was immunogenic polypeptide basic cellular localization modified (1997) (0)
Vaccinia Recombinants Expressing Foreign Antigens: Antiviral and Antitumor Immunity (1989) (0)
Viral vector coding for a glycoprotein of the virus responsible for AIDS vaccine, comprising the virus vector or the glycoprotein, as well as antibody to the glycoprotein (1987) (0)
Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1)--II. Synthetic peptides linked to HIV-1 carrier proteins gag and nef. (1991) (0)
Detection of gag-Specific Cytotoxic T Lymphocytes in HIV-2ben-Infected Macaques (1992) (0)
New Engineered Proteins for Use in Therapy and Vaccine Design (1990) (0)
LOSS OF CD4 MEMBRANE EXPRESSION AND CD4 rnRNA DURING ACUTE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BY PATRICK SALMON,* (2003) (0)
A pharmaceutical composition against tumors and infections papillomavirus (1996) (0)
Rabies vaccine and methods for preparing. (1985) (0)
Vaccine against rabies, as well as process for their preparation (1985) (0)
From vaccines to global health to vaccines (2018) (0)
A pharmaceutical composition for the treatment of papillomavirus tumors and infection (1997) (0)
Expression of human il-2 in mammalian cells by a pox virus recombines (1985) (0)
Proteins with glutathione S-transferase activity, DNA sequences, antibodies, pox viruses and drugs for prevention of schistosomiasis. (1987) (0)
A phase 1 clinical trial with a recombinant vaccinia virus expressing MUC1 and IL2 (1997) (0)
Perspectives on sexual transmission of Ebola virus: complementarity between research and public health intervention (2017) (0)
A pharmaceutical composition comprising a viral vector (1987) (0)
infections caused by papilloma viruses pharmaceutical composition against tumors and (1997) (0)
Expression vectors antigenic protein of rabies in eukaryotic cells and their application in the preparation of a vaccine (1983) (0)
[AIDS: vaccination against HIV]. (1992) (0)
Breast cancer immunotherapy: Preclinical study of a recombinant vaccinia virus vector expressing Muc1 and IL2 (1997) (0)
Towards a breast cancer vaccine (1989) (0)
Vaccination against rabies and process for its preparation (1984) (0)
antigenic protein of glycosylated rage (1984) (0)
Expression of a tumor-specific antigen, a recombinant virus vector as well as its application to the serving or curative treatment of the corresponding tumor. (1987) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Marie‐paule Kieny?

Marie‐paule Kieny is affiliated with the following schools:

Marie‐paule Kieny's Academic­Influence.com Rankings

Marie‐paule Kieny's Degrees

Why Is Marie‐paule Kieny Influential?

Marie‐paule Kieny's Published Works

Published Works

What Schools Are Affiliated With Marie‐paule Kieny?

Marie‐paule Kieny's AcademicInfluence.com Rankings